Page 63 - Read Online

Zerehpooshnesfchi et al. Metab Target Organ Damage. 2025;5:15 https://dx.doi.org/10.20517/mtod.2025.04 Page 9 of 11

Conflicts of interest
Lonardo A is Editor-in-Chief of the journal Metabolism and Target Organ Damage and the Guest Editor of
the Special Issue The Evolving Nomenclature of the Metabolic Fatty Liver Syndromes: NAFLD/NASH and
MAFLD/MASLD; Eslam M is an Editorial Board member of the journal. They were not involved in any
steps of editorial processing, notably including reviewer selection, manuscript handling, and decision
making. The other authors declared that there are no conflicts of interest.

Ethical Approval and Consent to Participate
Not applicable.

Consent for Publication
Not applicable.

Copyright
© The Author(s) 2025.

REFERENCES
1. Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-
analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107:2691-700. DOI PubMed
2. Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat
Rev Gastroenterol Hepatol. 2022;19:638-51. DOI PubMed
3. Eslam M, Fan JG, Yu ML, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis
and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025. DOI PubMed
4. Eslam M, Ahmed A, Després JP, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for
patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6:743-53. DOI PubMed
5. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc. 1980;55:434-8. PubMed
6. Yilmaz Y. The heated debate over NAFLD renaming: an ongoing saga. Hepatol Forum. 2023;4:89-91. DOI PubMed PMC
7. Eslam M, Fan JG, Mendez-Sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health.
Lancet Gastroenterol Hepatol. 2020;5:713-5. DOI PubMed
8. Byrne CD, Targher G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic
syndrome? Metab Target Organ Damage. 2024;4:10. DOI
9. Eslam M, George J. Two years on, a perspective on MAFLD. eGastroenterology. 2023;1:e100019. DOI PubMed PMC
10. Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert
consensus statement. Lancet Gastroenterol Hepatol. 2021;6:864-73. DOI PubMed
11. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international
expert consensus statement. J Hepatol. 2020;73:202-9. DOI PubMed
12. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic
associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1. DOI PubMed
13. Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the
diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. DOI PubMed
14. Fouad Y, Sanai F, Alboraie M, Zheng MH. What the new definition of MASLD left behind: dual etiology with viral hepatitis. Clin
Gastroenterol Hepatol. 2024;22:1751-2. DOI PubMed
15. Méndez-Sánchez N, Bugianesi E, Gish RG, et al; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global
multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388-90. DOI PubMed
16. Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr
Opin Gastroenterol. 2022;38:251-60. DOI PubMed
17. Alboraie M, Tanwandee T, Xu X, et al. Global multi-societies endorsement of the MAFLD definition. Ann Hepatol. 2024;29:101573.
DOI PubMed
18. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new
fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56. DOI PubMed
19. Fan JG, Xu XY, Yang RX, et al; Chinese Society of Hepatology, Chinese Medical Association. Guideline for the prevention and
treatment of metabolic dysfunction-associated fatty liver disease (version 2024). J Clin Transl Hepatol. 2024;12:955-74. DOI
PubMed PMC
20. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new